What is the prevalence of Juvenile Hyaline Fibromatosis?

Juvenile Hyaline Fibromatosis (JHF) is an ultra-rare genetic disorder with an estimated prevalence of less than 1 in 1,000,000 individuals worldwide. Because fewer than 100 cases have been documented in medical literature, the exact incidence remains unknown, and true prevalence is likely higher due to frequent underdiagnosis or misdiagnosis.

Is Juvenile Hyaline Fibromatosis considered rare?

Yes, Juvenile Hyaline Fibromatosis is classified as an ultra-rare disease. Due to its rarity, clinical data is limited, and many healthcare providers may never encounter a patient with the condition. At DiseaseMaps.org, we currently support 7 individuals living with Juvenile Hyaline Fibromatosis, providing a unique, though small, real-world perspective on the challenges of managing such a scarce condition.

Who is affected by Juvenile Hyaline Fibromatosis?

Juvenile Hyaline Fibromatosis affects males and females equally, with no known ethnic or geographic predilection. The condition is caused by mutations in the CMG2 (or ANTXR2) gene and follows an autosomal recessive inheritance pattern. Key epidemiological observations include:

• Age of Onset: Symptoms typically manifest in early childhood, often between birth and 4 years of age.


• Diagnostic Challenges: The rarity often leads to a significant "diagnostic odyssey," where patients may be misdiagnosed with other soft tissue tumors or inflammatory conditions before receiving a correct clinical or genetic diagnosis.


• Data Limitations: Because Juvenile Hyaline Fibromatosis is so rare, global registries struggle to capture accurate incidence rates, making it difficult to differentiate between true scarcity and clinical under-reporting.

How does underdiagnosis impact prevalence data?

The prevalence of Juvenile Hyaline Fibromatosis is almost certainly underestimated. Many mild cases may go undiagnosed, or symptoms may be attributed to more common dermatological or musculoskeletal issues. Accurate epidemiological mapping for Juvenile Hyaline Fibromatosis is hindered by the lack of large-scale, centralized international databases.

Next steps

• Consult a clinical geneticist to confirm a diagnosis through ANTXR2 gene sequencing.


• Connect with the community of 7 members at DiseaseMaps.org to share experiences and coping strategies.


• Monitor the NIH GARD database for updates on clinical trials and specialized centers of excellence.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: Portal for rare diseases and orphan drugs


• Online Mendelian Inheritance in Man (OMIM) entry #228600